US EditionLilly becomes first drugmaker to join trillion-dollar club on weight-loss demand boom
Lilly's weight-loss drugs generated nearly $19 billion in nine months, pushing its stock up over 35% this year amid soaring global obesity treatment demand.
- On Friday, Eli Lilly hit $1 trillion in market value, briefly touching the milestone in morning trade before retreating, becoming the first drugmaker to join the club.
- Growing demand for obesity drugs prompted Eli Lilly's shift after tirzepatide's approval helped it pivot from diabetes to obesity with Zepbound and Mounjaro, turning treatments into a lucrative segment.
- In the latest quarter, Lilly reported more than $10.09 billion from its obesity and diabetes portfolio, over half of $17.6 billion total revenue, and its stock rally has exceeded 35% this year.
- Wall Street projects the weight-loss market at $150 billion by 2030, with Lilly and Novo controlling most sales, while Lilly's White House pricing deal and production investments aim to support growth amid margin pressures.
- Investors are now focused on Lilly's oral obesity drug orforglipron, expected early next year, while Citi analysts say the GLP-1 class's success could boost its market entry against Novo Nordisk.
47 Articles
47 Articles
The world’s largest drug manufacturer, Eli Lilly, has just reached another milestone: it is the first health care company to cross the trillion dollar threshold, as investors are betting heavily on the manufacturer’s weight loss drugs. Lilly’s shares rose to 1.7 percent on Friday, raising its market value to about a trillion dollars, according to data collected by Bloomberg. With this breakthrough, Lilly has consolidated its position as the firs…
Eli Lilly joined the club of companies that have a stock market capitalization of one trillion dollars. The US pharmaceutical company is the first in the health area to achieve the milestone and belong to a group dominated by technology companies. Eli Lilly advanced enough to reach the trillion dollars. In view of the end of the day, the stock rose by 1.82% and reached a value of US$ 1.343 million. Thus, Eli Lilly joins the group of two non-tech…
Eli Lilly becomes first drugmaker to hit $1 trillion market value on weight-loss drug boom
Eli Lilly became the first drugmaker to reach a $1 trillion market valuation on Friday, driven by the rapid growth of its weight-loss drugs Mounjaro and Zepbound. The milestone highlights Lilly’s emergence as a major player in the booming obesity treatment market
Coverage Details
Bias Distribution
- 52% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
